Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Teva
Argus Health
Express Scripts
QuintilesIMS

Generated: August 22, 2019

DrugPatentWatch Database Preview

Patent: 5,776,456

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,776,456
Title: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Abstract:Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Inventor(s): Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Olivenhain, CA), Leonard; John E. (Encinitas, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Sante Fe, CA)
Assignee: IDEC Pharmaceuticals Corporation (San Diego, CA)
Application Number:08/476,275
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,776,456
Patent Claims:see list of patent claims

Details for Patent 5,776,456

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Sign Up IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 5,776,456

Country Patent Number Publication Date
South Africa 9308466 Jun 20, 1994
World Intellectual Property Organization (WIPO) 9411026 Aug 18, 1994
World Intellectual Property Organization (WIPO) 9411026 May 26, 1994
United States of America 2002197255 Dec 26, 2002
United States of America 2003021781 Jan 30, 2003
United States of America 2003082172 May 01, 2003
United States of America 2003095963 May 22, 2003
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Cantor Fitzgerald
Accenture
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.